Top U.S. Intravenous Immunoglobulin Companies

U.S. Intravenous Immunoglobulin Market size was valued at USD 7.02 Billion in 2024 and is poised to grow from USD 7.58 Billion in 2025 to USD 14.03 Billion by 2033, growing at a CAGR of 8% during the forecast period (2026–2033).

The top companies in the IVIG market in the US are concentrating on growth tactics such as product releases, R&D, mergers & acquisitions, and advancements in the IVIG products already on the market. 'Baxter International Inc. (US)', 'CSL Behring (US) ', 'Grifols, S.A. (Spain) ', 'Octapharma AG (Switzerland) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Biotest AG (Germany) ', 'Kedrion Biopharma (Italy) ', 'LFB Biotechnologies SAS (France) ', 'Bio Products Laboratory Ltd. (UK) ', 'China Biologic Products Holdings Inc. (China) ', 'Hualan Biological Engineering Inc. (China) ', 'Adma Biologics Inc. (US) ', 'Sanquin Plasma Products B.V. (Netherlands) ', 'Mitsubishi Tanabe Pharma Corporation (Japan) ', 'Green Cross Corporation (South Korea) ', 'Beijing Tiantan Biological Products Co., Ltd. (China) ', 'Jiangsu Institute of Hematology (China) ', 'Zhejiang Thaihot Bio-pharmaceutical Co., Ltd. (China) ', 'Tianjin Novolen Biological Pharmaceutical Co., Ltd. (China)'

Frozen dessert manufacturers continue to innovate and introduce new flavors, textures, and formats to cater to evolving consumer preferences. This includes offering healthier options, such as low-fat, low-sugar, and dairy-free alternatives, to meet the growing demand for healthier treats.

Indulgent and Decadent Treats: Despite the growing emphasis on healthier options, indulgence remains a strong driver in the frozen dessert market. Consumers still seek rich, creamy, and indulgent frozen treats like premium ice creams, gelatos, and decadent frozen novelties. Manufacturers continue to offer luxurious Flavors and textures to satisfy these cravings.

The Northeast region, comprising states such as New York, New Jersey, Massachusetts, Pennsylvania, and Connecticut, has a significant presence in the IVIG market. This region is home to renowned medical institutions, research facilities, and academic centers, which contribute to the availability and adoption of IVIG treatments. The dense population and advanced healthcare infrastructure in cities like New York City and Boston further enhance the prominence of the IVIG market in the Northeast.